Patient-Centred Care for Warfarin Management: A Pilot Study to Transition Care to High Risk Patients
Studieoversikt
Status
Status
Forhold
Forhold
Intervensjon / Behandling
Intervensjon / Behandling
Detaljert beskrivelse
50 patients will receive a cover letter outlining their random selection for this study, along with the patient information sheet and consent form (with a return addressed, postage paid envelope). Patients will be encouraged to contact the AC and speak with the Principal Investigator (TB) regarding the research study, and all questions will be addressed. We will continue this mailing process until a total of 50 patients have consented to study. PSM within the context of this study may use either POC technology or standard venipuncture with the patient accessing the laboratory for results. After receipt of consent, patients will be required to pass a foundational exam (outlining the basics of anticoagulation therapy, most of which should be simple review for the patients managed within our AC).4,10 Upon successfully passing this multiple choice exam, patients will be randomized to AC care (with no changes implemented) or to PSM.
PSM Phase I: Preparatory Phase of Patient Training (~6weeks) During the initial preparatory phase lasting 6 weeks + 2 weeks, the AC will create a patient specific warfarin dosing nomogram, discuss the same with the patient and ensure clear understanding, while working through various scenarios with the patient (Appendix 1). The AC will ensure the patient has an established system to both retrieve INR results (via POC technology or standard venipuncture) as well as to document the INR results, warfarin dosing, any pertinent assessment factors, and next date to test the INR. The AC will empower the patient to be proactive with coming up with warfarin dose changes during this preparatory phase.
PSM Phase II: Patient Practical Training:
The AC will enrol the patient into the PSM practical training phase (lasting 3 months + 1 month). At this time, the patient will retrieve their result and establish a future warfarin dose and follow-up plan. This information will be transmitted to a single AC team member. Contact with anotherdiscussed with an AC team member and the ultimate dosing decision will be tracked to ascertain concordance of the patient's original plan to what was implemented during the follow-up visit with the to perform standard AC teamcare and management will occur, thereby enabling comparison of the patient's plan and the AC plan. During this phase, the AC plan will be implemented. At the end of this phase, patients must pass a multiple choice exam that provides practical cases targeting warfarin dose adjustment with next scheduled follow-up visit, and will then be positioned into the PSM arm of the study.
Patient Self-Management During the PSM phase (6 months +/- 1 month), contact will occur with the AC monthly to retrieve INR results and warfarin dose adjustments (information from the patient-based charting system). Key points of contact between the patient and the AC will be required, such as: INR results either > 5.0 or 0.5 INR units below the lower limit of their desired target INR range, initiation of interacting medications, illness, etc. Patients not demonstrating the ability to self-manage their own warfarin therapy will be encouraged to cross-over to AC care. At the end of 6 months, patient choice of AC care or PSM will be identified.
Studietype
Studietype
Registrering (Faktiske)
Registrering
Fase
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
Alberta
-
Edmonton, Alberta, Canada, T6G 2J3
- University of Alberta
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- mechanical heart valve as the indication for warfarin
- > 16 years of age
- Warfarin therapy managed by the AC for at least the preceding 6 months
- Anticipated duration of warfarin therapy to be lifelong
- Previously adherent with medication
- Competence judged by demonstrated ability to use drug-adjustment nomograms
Exclusion Criteria:
• Severe psychiatric disease
- Significant language barrier
- Clinician's judgment that the patient would be a poor candidate for study (with reason specified)
- Known or anticipated procedure/surgery/intervention in the next year
- Active participation in another study
- Lack of access to the internet / email
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Helsetjenesteforskning
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Antall våpen
Våpen og intervensjoner
Deltakergruppe / ArmDeltakergruppe / Arm |
Intervensjon / BehandlingIntervensjon / Behandling |
|---|---|
|
Eksperimentell: Patient Self-Management
Patients will go through a preparatory phase (creation of warfarin dosing chart, process for documentation and retrieval of labs), a practical training phase (formulate warfarin management plan with support) and then perform patient-self management of their own warfarin.
|
Patient will manage their own warfarin therapy.
|
|
Ingen inngripen: Anticoagulation Clinic Care
Patients will not have their care altered, and will continue to be managed by our Anticoagulation Clinic.
|
Hva måler studien?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
The change in quality of life score (using the validated instruments DASS and Sawicki scale) between PSM and AC care.
Tidsramme: 6 months
|
Duke Anticoagulation Satisfaction Scale (DASS) and Sawicki Scale
|
6 months
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
The proportion of patients completing PSM
Tidsramme: 9 months
|
Beginning from consent and capturing stage at which patients withdrew (if applicable) namely the preparatory and practical training phases or PSM as well as those electing to continue PSM after study
|
9 months
|
|
Difference in the time in therapeutic INR range between those randomized to AC care versus PSM.
Tidsramme: 6 months
|
Time in range will be calculated using the Rosendaal method.
|
6 months
|
|
The rate of ER and hospitalization for anticoagulant and non-anticoagulant reasons between AC care and PSM.
Tidsramme: 6 months
|
presentations to hospital
|
6 months
|
|
The amount of time spent by the AC team for the AC group relative to the PSM group.
Tidsramme: 9 months
|
the number of minutes taken for each arm, as a measure of resource use within the AC team.
|
9 months
|
|
Amongst the PSM group, to determine if strategies for self-managing warfarin therapy have made patients do so for other chronic diseases.
Tidsramme: 6 months
|
a descriptive measure of translation of proactive management
|
6 months
|
|
Number of participants in AC care vs PSM that are dead at 5 years.
Tidsramme: 5 years following study completion
|
mortality measure
|
5 years following study completion
|
|
Number of encounters in the PSM group that put forward warfarin dosing that is concordant with that of the AC and to provide descriptions of warfarin dose changes.
Tidsramme: 3 months
|
assessed prior to entering the PSM phase
|
3 months
|
Samarbeidspartnere og etterforskere
Sponsor
Sponsor
Etterforskere
Etterforskere
- Hovedetterforsker: Tammy Bungard, BSP, PharmD, University of Alberta
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Studiestart
Primær fullføring (Faktiske)
Primær fullføring
Studiet fullført (Faktiske)
Studiet fullført
Datoer for studieregistrering
Først innsendt
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Først lagt ut
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Sist oppdatering lagt ut
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Andre studie-ID-numre
Andre studie-ID-numre
- Pro00052090
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Livskvalitet
-
NCT04706767FullførtDexmedetomidin | Lidokain | Quality of Recovery (QoR-40), Preoperativ og Postoperativ
-
NCT04528537FullførtPostoperativ Quality of Recovery i Postanesthesia Care Unit
-
NCT06815146Har ikke rekruttert ennåOpioidforbruk | Quality of Recovery (QoR-40), Preoperativ og Postoperativ
-
NCT06905353Har ikke rekruttert ennåPostoperativ kvalitet på utvinning | Postoperativ Quality of Recovery i Postanesthesia Care Unit
-
NCT02869711UkjentHealth Care Quality Management (ingen betingelse).
-
NCT07179289Aktiv, ikke rekrutterendeEvaluering av effekten av støtteverktøyet MSProgress Quality Approach på utviklingen av indikatorene som er valgt av MSP -ene sammenlignet med standardpleie
-
NCT06792669Fullført300 studenter ved University of Milan School of Medicine
-
NCT06102200FullførtVelferdstandard | Standard of Care + CBT4CBT | Standard of Care + CBT4CBT + RC
-
NCT07580456Har ikke rekruttert ennåPoint-of-care ultralyd
-
NCT06529315FullførtPoint-of-care ultralyd
Kliniske studier på Patient Self-Management
-
NCT05491252Fullført
-
NCT01916655FullførtObstruktiv søvnapné
-
NCT06037785RekrutteringImplanterbar defibrillatorbruker | Stressreaksjon | Ptsd | Stressmestring | Sosial kognitiv teori
-
NCT01182480Fullført
-
NCT05939297FullførtKoronararteriesykdom
-
NCT04116463Fullført
-
NCT05460156FullførtNevromuskulære sykdommer
-
NCT01351662FullførtSystemisk lupus erythematosus
-
NCT06588647Rekruttering